Quarterly report pursuant to Section 13 or 15(d)

Supplemental Information (Tables)

v3.24.2.u1
Supplemental Information (Tables)
 6 Months Ended
Jun. 30, 2024
Product Information [Line Items]  
Schedule of Discontinued Operation

A summary of the Lyte discontinued operation in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2023 is set forth below:

 

    Three     Six  
    Months Ended June 30, 2023     Months Ended June 30, 2023  
Net revenues   $ 2,192     $ 5,594  
Cost of revenues     2,272       5,386  
Gross profit     (80 )     208  
                 
Operating expenses:                
Sales and marketing     331       603  
General and administrative     496       1,069  
Impairment of goodwill     1,203       1,203  
Total operating expenses     2,030       2,875  
Operating loss   $ (2,110 )   $ (2,667 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth common stock equivalents that have been excluded from the computation of dilutive weighted average shares outstanding as their inclusion would have been anti-dilutive:

 

    2024     2023  
    June 30,  
    2024     2023  
Warrants     -       125,103  
Options     8,323       18,091  
Restricted stock units     70,223       96,878  
Total     78,546       240,072  
Accounts Receivable [Member]  
Product Information [Line Items]  
Schedule of Concentration of Credit Risk of Accounts Receivable

Collateral is not required for accounts receivable, and we believe the carrying value approximates fair value. The following table sets forth our concentration of accounts receivable, net of specific allowances for doubtful accounts.

 

    June 30,
2024		    

December 31,

2023

  
Customer A     0 %     43 %
Customer B     12 %     16 %
Customer C     3 %     12 %
Customer D     36 %     0 %
Customer E     17 %     0 %